-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Analyzing Standard BioTools (NASDAQ:LAB) & Pacific Biosciences of California (NASDAQ:PACB)
Analyzing Standard BioTools (NASDAQ:LAB) & Pacific Biosciences of California (NASDAQ:PACB)
Standard BioTools (NASDAQ:LAB – Get Rating) and Pacific Biosciences of California (NASDAQ:PACB – Get Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.
Profitability
This table compares Standard BioTools and Pacific Biosciences of California's net margins, return on equity and return on assets.
Get Standard BioTools alerts:Net Margins | Return on Equity | Return on Assets | |
Standard BioTools | -163.64% | -2,049.96% | -24.12% |
Pacific Biosciences of California | -218.44% | -42.03% | -15.59% |
Analyst Recommendations
This is a summary of current recommendations for Standard BioTools and Pacific Biosciences of California, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Standard BioTools | 0 | 0 | 0 | 0 | N/A |
Pacific Biosciences of California | 0 | 3 | 3 | 0 | 2.50 |
Insider & Institutional Ownership
63.2% of Standard BioTools shares are owned by institutional investors. Comparatively, 92.9% of Pacific Biosciences of California shares are owned by institutional investors. 51.6% of Standard BioTools shares are owned by insiders. Comparatively, 1.4% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Standard BioTools and Pacific Biosciences of California's gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Standard BioTools | $109.19 million | 1.51 | -$59.24 million | ($2.30) | -0.90 |
Pacific Biosciences of California | $130.51 million | 20.06 | -$181.22 million | ($1.34) | -8.64 |
Standard BioTools has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Standard BioTools has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.
Summary
Pacific Biosciences of California beats Standard BioTools on 9 of the 13 factors compared between the two stocks.
About Standard BioTools
(Get Rating)
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.
About Pacific Biosciences of California
(Get Rating)
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with MarketBeat.com's FREE daily email newsletter.
Standard BioTools (NASDAQ:LAB – Get Rating) and Pacific Biosciences of California (NASDAQ:PACB – Get Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.
标准生物工具公司(纳斯达克:LAB-GET评级)和加州太平洋生物科学公司(纳斯达克:PACB-GET评级)都是医疗公司,但哪项业务更优越?我们将根据这两家公司的股息、分析师建议、收益、风险、估值、盈利能力和机构持股情况对它们进行比较。
Profitability
盈利能力
This table compares Standard BioTools and Pacific Biosciences of California's net margins, return on equity and return on assets.
此表比较了标准生物工具公司和太平洋生物科学公司对加州净利润率、股本回报率和资产回报率的影响。
Net Margins | Return on Equity | Return on Assets | |
Standard BioTools | -163.64% | -2,049.96% | -24.12% |
Pacific Biosciences of California | -218.44% | -42.03% | -15.59% |
净利润率 | 股本回报率 | 资产回报率 | |
标准生物工具 | -163.64% | -2,049.96% | -24.12% |
加州太平洋生物科学 | -218.44% | -42.03% | -15.59% |
Analyst Recommendations
分析师建议
This is a summary of current recommendations for Standard BioTools and Pacific Biosciences of California, as provided by MarketBeat.com.
这是对加州标准生物工具和太平洋生物科学的当前建议的摘要,由MarketBeat.com提供。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Standard BioTools | 0 | 0 | 0 | 0 | N/A |
Pacific Biosciences of California | 0 | 3 | 3 | 0 | 2.50 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
标准生物工具 | 0 | 0 | 0 | 0 | 不适用 |
加州太平洋生物科学 | 0 | 3 | 3 | 0 | 2.50 |
Insider & Institutional Ownership
内部人与机构所有权
63.2% of Standard BioTools shares are owned by institutional investors. Comparatively, 92.9% of Pacific Biosciences of California shares are owned by institutional investors. 51.6% of Standard BioTools shares are owned by insiders. Comparatively, 1.4% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
标准生物工具63.2%的股份由机构投资者持有。相比之下,加州太平洋生物科学公司92.9%的股份由机构投资者持有。标准生物工具公司51.6%的股份由内部人士持有。相比之下,加州太平洋生物科学公司1.4%的股份由内部人士持有。强大的机构持股表明,捐赠基金、大型基金管理公司和对冲基金相信,一家公司的长期表现将好于大盘。
Valuation & Earnings
估值与收益
This table compares Standard BioTools and Pacific Biosciences of California's gross revenue, earnings per share (EPS) and valuation.
此表比较了标准生物工具公司和太平洋生物科学公司对加州总收入、每股收益(EPS)和估值的影响。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Standard BioTools | $109.19 million | 1.51 | -$59.24 million | ($2.30) | -0.90 |
Pacific Biosciences of California | $130.51 million | 20.06 | -$181.22 million | ($1.34) | -8.64 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
标准生物工具 | 1.0919亿美元 | 1.51 | -5924万美元 | ($2.30) | -0.90 |
加州太平洋生物科学 | 1.3051亿美元 | 20.06 | -1.8122亿美元 | ($1.34) | -8.64 |
Standard BioTools has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.
与加州的太平洋生物科学公司相比,标准生物工具公司的收益更高,但收入更低。加州太平洋生物科学的市盈率低于标准生物工具,表明它目前是两只股票中更负担得起的一只。
Volatility and Risk
波动性和风险
Standard BioTools has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.
Standard BioTools的贝塔系数为1.51,表明其股价的波动性比标准普尔500指数高出51%。相比之下,加州太平洋生物科学公司的贝塔系数为1.67,这表明其股价的波动性比标准普尔500指数高67%。
Summary
摘要
Pacific Biosciences of California beats Standard BioTools on 9 of the 13 factors compared between the two stocks.
在比较两只股票的13个因素中,加州太平洋生物科学公司在9个方面击败了标准生物工具公司。
About Standard BioTools
关于标准生物工具公司
(Get Rating)
(获取评级)
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.
标准生物工具公司致力于为临床研究提供生物技术工具和服务。它销售用于质量细胞术、聚合酶链式反应、文库准备、单细胞基因组学的准备和分析仪器,以及包括集成电路(IFCs)、分析和试剂在内的消耗品。该公司由斯蒂芬·D·奎克和加朱·文森特·沃辛顿于1999年5月19日创立,总部设在加利福尼亚州旧金山南部。
About Pacific Biosciences of California
关于加州的太平洋生物科学
(Get Rating)
(获取评级)
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
加利福尼亚太平洋生物科学公司致力于开发、制造和营销用于基因分析的先进测序解决方案。它通过以下地理细分市场运营:北美、欧洲和亚太地区。该公司由斯蒂芬·特纳和约瑟夫·文森特·邦文垂于2000年7月14日创立,总部设在加利福尼亚州门洛帕克。
Receive News & Ratings for Standard BioTools Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard BioTools and related companies with MarketBeat.com's FREE daily email newsletter.
获得《标准生物工具日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Standard BioTools和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧